Shehzin

@livingbeyondbc | Mama 👶🏽 | International Trade | Tech | Patient Advocate #breastcancer | formerly @gdecd

[Shehzin @ShehzinT]

@stage4kelly @UCSFCancer @BalassanianRon @hoperugo Ugh so sorry to hear this Kelly, grateful you are in the BEST hands. sending hugs and positive energy for finding good targets for treatment 💚

[Shehzin @ShehzinT]

@christeeny513 💔 Grateful for you and your dedication to the community and research. My WHY as well ❤️

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

Dr. Richard Gray walks thru a meta-analysis of nearly 15K premenopausal women that reveals for pre-menopausal women <45, ovarian ablation or suppression ⬇️15-year risk of recurrence and death from breast cancer without increasing mortality from other causes #ASCO23

[Stacey Tinianov (she/her) MPH, BCPA @coffeemommy]

A shared decision-making reality slide from @jillfeldman4 complete with impacts to life well beyond AEs/SEs. Risk/benefit data is important but start with asking "what matters to YOU?" #ASCO23 cc: @OncoAlert @AdvocateCollab
#lcsm #bcsm #crcsm #gyncsm #SurvOnc

[Shehzin @ShehzinT]

Great start to #ASCO23 with my fellow YoungAdvocate Jamil @chrysalisinit Look at us doing all the things! Thanks @GileadOncology for bringing us together and including me with these brilliant #breastcancer orgs @LivingBeyondBC @CancerSupportHQ @RickiDOVE @OncNav @BreastCancerCDN

[Living Beyond Breast Cancer @LivingBeyondBC]

This month, the U.S. Preventive Services Task Force (USPSTF) recommended lowering the age at which women at average risk for #breastcancer should begin mammography screening to 40 years old. Learn more: https://t.co/IqNePxkI1v #bcsm

[Living Beyond Breast Cancer @LivingBeyondBC]

Ricki Fairley, CEO of @touchbbca and longtime partner of LBBC, explains how the new breast cancer screening guidance "does NOT apply to women with dense breasts, Black women, or women with a family history of breast cancer." #bcsm https://t.co/YJ1T0yMkn5

[Paolo Tarantino @PTarantinoMD]

With #ASCO23-week officially here, it is time for a #top10 list of breast abstracts! Several potentially practice-changing trials to be presented during the congress. Take a look, share if you found it useful and feel free to recommend additional impactful abstracts to add! #bcsm

[SteegeThomson @SteegeThomson]

Young women with breast cancer face under-recognized sexual & reproductive health challenges. In this impactful piece by @MissMeghanMack @TODAYshow, personal stories from @ShehzinT & Sara Montiel illustrate the importance of @LivingBeyondBC Arin Ahlum Hanson's research findings.

[Living Beyond Breast Cancer @LivingBeyondBC]

Today at 5pm at #SABCS22, we will share results of our national survey about young women with #breastcancer, including the need for more information about sexual/reproductive health (poster PD8-07). Read more in this article from @HealthDayTweets. https://t.co/BABoUKeJRK

[Winship Cancer Institute of Emory University @WinshipAtEmory]

Winship breast oncologist Kevin Kalinsky, MD, MS, shared RxPONDER trial results today at the 2022 San Antonio Breast Cancer Symposium showing Black women with HR+/HER2- breast cancer have worse outcomes than other racial and ethnic groups. #SABCS22 ➡️ https://t.co/uEa9QaiUfP

[Shehzin @ShehzinT]

@ATLDOT @ATLDOT when is the projected completion and reopening? Some Atlanta residents have been taking detours since August 2021 :/

[STAT @statnews]

A STAT investigation found that Black residents leave or are terminated from training programs at far higher rates than white residents. https://t.co/ASGTDBqSv3

[Shehzin @ShehzinT]

One of the biggest pieces of #cancer news to come out of #ASCO22: Overall survival benefit for HER2-low patients with #metatasticbreastcancer on Enhertu. While we can do better than 6 months, still amazing news for many in this patient group. Read more on https://t.co/SIhKErP58H

[Living Beyond Breast Cancer @LivingBeyondBC]

Findings yesterday at #ASCO22 likely create new treatment target for people with HER2-low (IHC 1+ and 2+) HR+ #metastaticbreastcancer, and possibly for those with mTNBC as well. Learn more about the landmark DESTINY-Breast04 trial in our ASCO coverage: https://t.co/rszx0O0JiW

[Catherine Ormerod @cormerod]

The impact of patients who became advocates was fully on display #ASCO2022. Advocates are not waiting to be asked to come to the party. They’re leading and contributing already. @faceofstage4 @mbcalliance @LesleyKailani @JaniceTNBCmets @swaggsheila1 @Maimah @touchbbca @jamilkali

[Ilana Schlam @IlanaSchlam]

Wrapping up #ASCO22 and thinking how to incorporate the practice changing research presented here 🟠. HER2 low will change the way we think about 50% of our metastatic patients. What are you doing Wednesday morning? @DrSGraff @stolaney1 @DrGattiMays @ErikaHamilton9 @OncoAlert

[Living Beyond Breast Cancer @LivingBeyondBC]

Patient navigators are playing a critical role in how the state of Delaware has reduced its cancer death rates and narrowed racial disparities in some forms of cancer: https://t.co/nPMyU8ZnQL #bcsm

[Eli Lilly and Company @EliLillyandCo]

Lilly is collaborating with @Breastcancerorg, @thebreastofus, @LivingBeyondBC, and @SusanGKomen to launch an education campaign that provides resources for understanding the complexities of early breast cancer. https://t.co/LVPgnp3bZG #breastcancer

[Shehzin @ShehzinT]

@stage4kelly @ASCO Thanks for the summary Kelly! I was curious about this one.